Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889475 | 0.87 | — | — | |
| SCHEMBL21651112 | 0.75 | ALDH1A1 (0.33) | ALDH1A1MAPTPOLBMT-CO2 | |
| SCHEMBL26983541 | 0.71 | — | — | |
| SCHEMBL3938297 | 0.71 | — | — | |
| SCHEMBL9836228 | 0.71 | TRIM24 (0.32) | ALDH1A1 | |
| SCHEMBL9836224 | 0.71 | TRIM24 (0.32) | ALDH1A1 | |
| SCHEMBL9688152 | 0.69 | ALDH1A1 (0.35) | ALDH1A1MAPTPOLB | |
| SCHEMBL8595012 | 0.69 | NOS3 (0.30) | — | |
| SCHEMBL27439304 | 0.68 | MAPT (0.38) | ALDH1A1MAPTPOLB | |
| SCHEMBL3936524 | 0.68 | MAPT (0.38) | ALDH1A1MAPTPOLBMT-CO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046147-B1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2013-05-01 | — | — | EP | claimed |
| US-20090311403-A1 | Method of Using Organic Compounds | GIVAUDAN SA (CH) | 2009-12-17 | — | — | US | claimed |
| EP-2046147-B1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2013-05-01 | — | — | EP | disclosed |
| US-20090311403-A1 | Method of Using Organic Compounds | GIVAUDAN SA (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-2046147-A1 | METHOD OF USING ORGANIC COMPOUNDS | Givaudan SA (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008011742-A1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-01-31 | — | — | WO | disclosed |
| EP-0550111-B1 | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them | SANOFI SA (FR) | 1999-04-14 | — | — | EP | disclosed |
| US-5856349-A | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | SANOFI (FR) | 1999-01-05 | — | — | US | disclosed |
| US-5783589-A | 2-saccharinylmethyl aryl and arloxy acetates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | SANOFI (FR) | 1998-07-21 | — | — | US | disclosed |
| US-5652254-A | TREATMENT OF DEGENERATIVE DISEASES, RHEUMATOID ARTHRITIS, PSORIASIS, CYSTIC FIBROSIS | SANOFI, S.A. (FR) | 1997-07-29 | — | — | US | disclosed |
| US-5597841-A | 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP, INC. (US) | 1997-01-28 | — | — | US | disclosed |
| US-5385923-A | Treatment of degenerative diseases | STERLING WINTHROP INC. (US) | 1995-01-31 | — | — | US | disclosed |
| US-5376653-A | A protease enzyme inhibitor for treating degenerative diseases , respiratory system disorders, rheumatoid arthritis and pancreatitis | STERLING WINTHROP INC. (US) | 1994-12-27 | — | — | US | disclosed |
| US-5306818-A | Treating degenerative diseases such as emphysema, rheumatoid arthritis and pancreatitis | STERLING WINTHROP INC. (US) | 1994-04-26 | — | — | US | disclosed |
| US-5262549-A | Visible and near infra-red absorbers for images | POLAROID CORPORATION (US) | 1993-11-16 | — | — | US | disclosed |
| US-5250696-A | Treatment of degenerative diseases | STERLING WINTHROP INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0550111-A1 | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them | STERLING WINTHROP INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0550112-A1 | 2-Saccharinylmethyl aryl and aryloxy acetates useful as proteolytic enzyme inhibitors and pharmaceutical compositions contaning them | STERLING WINTHROP INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| US-5128339-A | Emphysema, rheumatoid arthritis, pancreatitis | STERLING WINTHROP INC. (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0483928-A1 | 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use | STERLING WINTHROP INC. (US) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311403-A1 | Method of Using Organic Compounds | MGLL, GK, LIPC | ALDH1A1 788/4885MAPT 2208/4885POLB 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.